Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS ≥3) recurrent ovarian cancer (ROC) receiving ≥3 lines of chemotherapy: The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).

被引：0
|
作者：
Roncolato, Felicia T.
O'Connell, Rachel
Joly, Florence
Lanceley, Anne
Hilpert, Felix
Okamoto, Aikou
Aotani, Eriko
Pignata, Sandro
Donnellan, Paul P.
Oza, Amit M.
Avall-Lundqvist, Elisabeth
Berek, Jonathan S.
Sjoquist, Katrin Marie
Gillies, Kim
Butow, Phyllis
Stockler, Martin R.
King, Madeleine Trudy
Friedlander, Michael
机构：
[1] Univ Sydney, NHMRC Clin Trials Ctr, ANZGOG, Camperdown, NSW, Australia
[2] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia
[3] Ctr Francois Baclesse, F-14021 Caen, France
[4] UCL, Teaching Hosp, London, England
[5] Univ Schleswig Holstein, Dept Obstet & Gynecol, Kiel, Germany
[6] Jikei Univ, Sch Med, Tokyo, Japan
[7] Kitasato Univ, Kitasato Acad Res Org, Minato Ku, Tokyo, Japan
[8] Natl Canc Inst Naples, Naples, Italy
[9] Galway Univ Hosp, Galway, Ireland
[10] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[11] Linkoping Univ, Dept Oncol, Linkoping, Sweden
[12] Linkoping Univ, Dept Clin Expt Med, Linkoping, Sweden
[13] Karolinska Inst, Linkoping, Sweden
[14] Stanford Womens Canc Ctr, Stanford, CA USA
[15] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia
[16] St George Hosp, Canc Care Ctr, Sydney, NSW, Australia
[17] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia
[18] Univ Sydney, Sydney, NSW 2006, Australia
[19] Univ Sydney, Psychooncol Cooperat Res Grp PoCoG, Sydney, NSW 2006, Australia
[20] Prince Wales Canc Ctr, Randwick, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.5564
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5564
引用
收藏
页数：1
相关论文
共 19 条
  • [1] BASELINE PREDICTORS OF EARLY TREATMENT FAILURE IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY (PRR) AND POTENTIALLY PLATINUM SENSITIVE (PPS) RECURRENT OVARIAN CANCER (ROC) RECEIVING ≥3 LINES OF CHEMOTHERAPY- THE GYNAECOLOGIC CANCER INTERGROUP (GCIG) SYMPTOM BENEFIT STUDY (SBS)
    Roncolato, Felicia
    O'Connell, Rachel
    Joly, Florence
    Lanceley, Anne
    Hilpert, Felix
    Okamoto, Aikou
    Aotani, Eriko
    Pignata, Sandro
    Donnellan, Paul
    Oza, Amit
    Avall-Lundqvist, Elizabeth
    Berek, Jonathan
    Sjoquist, Katrin
    Gillies, Kim
    Butow, PhyllisPhyllis
    Stockler, Martin
    King, Madeleine
    Friedlander, Michael
    Kok, Peey-Sei
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 125 - 125
  • [2] Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC)?: Symptom burden and outcomes in patients with platinum resistant/ refractory (PRR) and potentially platinum sensitive ROC receiving ≥ 3 lines of chemotherapy (PPS ≥ 3)-The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).
    Friedlander, Michael
    Stockler, Martin R.
    O'Connell, Rachel
    Joly, Florence
    Lanceley, Anne
    Hilpert, Felix
    Okamoto, Aikou
    Aotani, Eriko
    Pignata, Sandro
    Donnellan, Paul P.
    Oza, Amit M.
    Avall-Lundqvist, Elisabeth
    Berek, Jonathan S.
    Sjoquist, Katrin Marie
    Gillies, Kim
    Butow, Phyllis
    King, Madeleine Trudy
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] IS IT TIME TO CHANGE THE PRIMARY ENDPOINT IN CLINICAL TRIALS IN RECURRENT OVARIAN CANCER (ROC)? SYMPTOM BURDEN AND OUTCOMES IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY (PRR) AND POTENTIALLY PLATINUM SENSITIVE ROC RECEIVING ≥3 LINES OF CHEMOTHERAPY (PPS) - THE GYNECOLOGIC CANCER INTERGROUP (GCIG) SYMPTOM BENEFIT STUDY (SBS)
    Friedlander, Michael
    Stockler, Martin
    O'Connell, Rachel
    Joly, Florence
    Lanceley, Anne
    Hilpert, Felix
    Okamoto, Aikou
    Aotani, Eriko
    Pignata, Sandro
    Donnellan, Paul
    Oza, Amit
    Avall-Lundqvist, Elisabeth
    Berek, Jonathan
    Sjoquist, Katrin
    Gillies, Kim
    Butow, Phyllis
    King, Madeleine T.
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 111 - 111
  • [4] Symptom burden and outcomes in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive ROC receiving ≥ 3 lines of chemotherapy (PPS ≥ 3) - GCIG Symptom Benefit Study (AGO PRO1).
    Hipert, F.
    Friedlander, M.
    Stockler, M.
    O'Connell, R.
    Joly, F.
    Lanceley, A.
    Okamoto, A.
    Aotani, E.
    Pignata, S.
    Donnellan, P.
    Oza, A.
    Avall-Lundqvist, E.
    Berek, J.
    Sjoquist, K.
    Gillies, K.
    Butow, P.
    King, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 138 - 139
  • [5] Predictors of stopping chemotherapy early and short survival in patients with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) who have had ≥3 lines of prior chemotherapy: The GCIG symptom benefit study (SBS).
    Roncolato, Felicia
    Joly, Florence
    O'Connell, Rachel
    Lanceley, Anne
    Heitz, Florian
    Buizen, Luke
    Okamoto, Aikou
    Aotani, Eriko
    Salutari, Vanda
    Donnellan, Paul P.
    Oza, Amit M.
    AvalI-Lundqvist, Elisabeth
    Berek, Jonathan S.
    Hilpert, Felix
    Feeney, Amanda
    Roemer-Becuwe, Celia
    Stockier, Martin R.
    King, Madeleine Trudy
    Friedlander, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS)
    Roncolato, F. T.
    O'Connell, R. L.
    Joly, F.
    Lanceley, A.
    Hilpert, F.
    Buizen, L.
    Okamoto, A.
    Aotani, E.
    Salutari, V
    Donnellan, P.
    Oza, A.
    Avall-Lundqvist, E.
    Berek, J.
    Fehm, T.
    Ledermann, J.
    Roemer-Becuwe, C.
    Stockler, M. R.
    King, M. T.
    Friedlander, M. L.
    GYNECOLOGIC ONCOLOGY, 2020, 156 (01) : 45 - 53
  • [7] TRABECTEDIN ALLOWS RETREATMENT WITH PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT/REFRACTORY (PRR) AND PARTIALLY PLATINUM-SENSITIVE (PPS) RECURRENT OVARIAN CANCER (ROC)
    Callata, H.
    Manzano, A.
    Sanchiz, B.
    Alonso, T.
    Gajate, P.
    Cabezas, S.
    Sotelo, M.
    Aguado, C.
    Diaz-Rubio, E.
    Casado, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [8] Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG symptom benefit study (SBS).
    Roncolato, Felicia
    O'Connell, Rachel
    Buizen, Luke
    Joly, Florence
    Lanceley, Anne
    Hilpert, Felix
    Okamoto, Aikou
    Aotani, Eriko
    Pignata, Sandro
    Donnellan, Paul P.
    Oza, Amit M.
    Avall-Lundqvist, Elisabeth
    Berek, Jonathan S.
    Sjoquist, Katrin Marie
    Gillies, Kim
    Stockler, Martin R.
    King, Madeleine Trudy
    Friedlander, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study
    Roncolato, Felicia T.
    Joly, Florence
    O'Connell, Rachel
    Lanceley, Anne
    Hilpert, Felix
    Buizen, Luke
    Okamoto, Aikou
    Aotani, Eriko
    Pignata, Sandro
    Donnellan, Paul
    Oza, Amit
    Avall-Lundqvist, Elisabeth
    Berek, Jonathan S.
    Heitz, Florian
    Feeney, Amanda
    Berton-Rigaud, Dominique
    Stockler, Martin R.
    King, Madeleine
    Friedlander, Michael
    ONCOLOGIST, 2017, 22 (09): : 1117 - 1124
  • [10] RECHALLENGE WITH PLATINUM-BASED CHEMOTHERAPY AFTER TRABECTEDIN IN HEAVELY PRE-TREATED PATIENTS WITH PLATINUM-RESISTANT/REFRACTORY (PRR) AND PARTIALLY PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER (PPS-ROC)
    Casado, A.
    Callata Carhuapoma, H. R.
    Sanchiz, B.
    Manzano Fernandez, A.
    Sotelo Lezama, M. J.
    Cabezas-Camarero, S.
    Aguado De La Rosa, C.
    Coronado, P.
    Vidart Aragon, J. A.
    Diaz-Rubio Garcia, E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 468 - 469
12